Topic: Blue Chip Stocks

Strong product pipeline spurs growth as industry leader weighs possible spinoff

This stock is re-organizing and reviewing its operations, which could result in a spinoff or sale of one of its major divisions.  

At the same time, the pharma giant continues to spend heavily to maintain its strong drug pipeline. It is also making key acquisitions to fend off competition from generic drugmakers. The company’s balance sheet is strong, and it is rewarding investors with share buybacks. It has also increased its dividend for each of the past seven years.


Do You Own Any U.S. Stocks?

Time to see what the best U.S. stocks will do for you

The most successful Canadian investors have at least 20% of their portfolios in U.S. stocks to build the power of their portfolios.

Click here to find the best US stocks >>
 

PFIZER INC. (New York symbol PFE; www.pfizer.com) is one of the world’s largest makers of prescription drugs. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain), Prevnar (pneumonia) and Enbrel (rheumatoid arthritis).

Pfizer’s revenue fell 5.3%, from $51.6 billion in 2013 to $48.9 billion in 2015. That decline is partly because it continues to face more competition from generic drugs as many of its main products lose their patent protection.

In response, the company has purchased smaller drugmakers with promising products. Those include its September 2015 acquisition of Hospira for $17 billion. That firm makes copies of biologic drugs that have lost their patent protection.

Thanks to those new businesses, Pfizer’s revenue improved to $52.8 billion in 2016. However, revenue dipped 0.5% to $52.5 billion in 2017. That’s because the company sold its Hospira Infusion Systems business for $900 million. That operation makes intravenous pumps. If you factor out those products and foreign exchange rates, revenue gained 1.5% for the year.

Overall earnings fell 10.0%, from $15.3 billion in 2013 to $14.5 billion in 2014. However, earnings per share gained 1.8%, from $2.22 to $2.26, on fewer shares outstanding. Pfizer’s earnings then fell to $2.20 a share (or a total of $13.8 billion) in 2015, before rebounding to $2.40 a share (or $14.8 billion) in 2016, and rising again in 2017 to $2.65 a share (or $16.1 billion).

In the second quarter of 2018, the company’s earnings jumped 18.8%, to $4.8 billion from $4.1 billion a year earlier. Due to fewer shares outstanding, earnings per share improved 20.9%, to $0.81 from $0.67.

The higher earnings are partly due to cost savings following the Hospira purchase. Pfizer expects to cut $1 billion from its annual costs by the end of 2018. The recent U.S. tax reforms also lowered its effective tax rate in the latest quarter to 14.3% from 19.4% a year earlier.

Revenue rose 4.4%, to $13.5 billion from $12.9 billion on stronger sales of new drugs such as Eliquis (anti-stroke), Ibrance (a cancer treatment) and Xeljanz (arthritis), and biosimilars.

Blue Chip Stocks: New pain treatment could become a viable alternative to opioid painkillers

Starting next year, the company plans to reorganize its operations into three new businesses: Innovative Medicines (including biosimilar drugs and hospital products); Established Medicines (including some generic brand drugs); and Consumer Healthcare (over-the-counter treatments).

Pfizer continues to consider selling or spinning off its Consumer division, which accounts for 7% of its overall revenue. The reorganization should make it easier for potential buyers to evaluate that business’s performance. The company expects to complete the review by the end of 2018.

Meantime, Pfizer continues to spend heavily to develop new drugs. It spent $1.80 billion (or 13.3% of revenue) on research in the second quarter. That’s up 0.6% from $1.79 billion (or 13.9% of revenue) a year earlier.

For all of 2018, the drugmaker plans to increase research spending to between $7.7 billion and $8.1 billion. That’s up from its earlier forecast of $7.4 billion to $7.9 billion.

The increased spending should help Pfizer bring several late-stage drugs to market. It expects regulators will approve 25 to 30 of its new drugs through 2022. Those include 15 that could each generate $1 billion in annual sales.

For example, the company and Eli Lilly Co. (New York symbol LLY) have jointly developed a new pain treatment, Tanezumab. The drug, currently in Phase 3 clinical trials, could become a viable alternative to opioid painkillers.

Pfizer also has high hopes for Tafamidis. That drug is a treatment for a rare form of heart disease. Based on early trials, Tafamidis reduces the risk of death by 30%. The Food and Drug Administration recently designated the drug as a breakthrough medical therapy. That should speed up its approval.

The company also announced that it would spend $465 million to build a major new production facility in Portage, Michigan. The new plant should begin operating in 2024.

Pfizer’s strong balance sheet will let it continue to keep investing in its operations. As of July 1, 2018, the company’s long-term debt was $28.9 billion, or just 11% of its market cap. Pfizer also held cash and investments of $13.4 billion, or $2.29 a share.

The company is also using its cash to buy back its shares. In the first half of 2018, Pfizer spent $6.1 billion on share repurchases. Under its current authorization, the company can still buy back up to $10.3 billion of its shares. There are no time limits for those purchases.

Starting with the March 2018 payment, Pfizer increased its quarterly dividend by 6.3%, to $0.34 a share from $0.32. The new annual rate of $1.36 yields 3.1%. The company has now increased the annual rate each year since 2011.

For all of 2018, Pfizer expects to earn between $2.95 and $3.05 a share. The stock trades at just 14.8 times the midpoint of that range.

We will update Pfizer’s third quarter earnings in a future issue of Wall Street Stock Forecaster.

Recommendation in Wall Street Stock Forecaster: Pfizer is a buy.

 


It’s Financial Literacy Month in Canada: this Friday, see how to further your investment knowledge in our Daily Advice column.

Invest in your financial well-being


What to Read Next 

Bank gets bigger on both sides of border

How to shop for greater safety

Comments

  • PFE is poised to go higher (I own it). Recently opened a position on Lilly (LLY) as they are another big pharma company poised to move higher.

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.